Tenaya Therapeutics Q2 net loss $23.3M; cash runway into H2 2026; TN-201/401 data Q4 2025

Tenaya Therapeutics, Inc.

2025-Q2 EPS reported -$0.37

Net loss $23.3M ($0.14 loss per share) vs $29.4M ($0.34) in Q2 2024.
Cash, equivalents and marketable securities $71.7M as of June 30, 2025; runway into H2 2026.
TN-201 for HCM: Cohorts 1 & 2 enrollment complete; DSMB allows expansion; data readout Q4 2025.
TN-401 for ARVC: Cohort 1 enrolled; DSMB recommends dose escalation; first patient dosed in Cohort 2; data Q4 2025.
R&D expense $17.4M vs $22.6M YoY; G&A $6.7M vs $8.2M YoY.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.